Report: Pfizer set to cut sales force by up to 2,400 reps

Share this article:

Pfizer could reduce its sales force by one-third, or 2,400 reps, according to a Bloomberg report that cited anonymous sources.

The layoffs would come ahead of looming patent expiries. Lipitor, the company's blockbuster cholesterol drug, will face generic competition as early as 2011.

Bloomberg reported that Deutsche Bank analyst Barbara Ryan said in an interview last month that Pfizer CEO Jeffrey Kindler might detail new cost-cutting plans at an investor presentation on January 28. Ray Kerins, a company spokesperson, told Bloomberg that Pfizer's plan is to “reshape our company into smaller, more focused units to best deploy our valuable resources and drive decision-making closer to our customers and to the markets in which we operate.”

On January 13, Pfizer announced plans to cut up to 800 research jobs in 2009. Those cuts represent 5-8% of the company's approximately 10,000 researchers.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...